The Europe Diabetic Neuropathy Market was worth USD 1.38 billion in 2022 and is estimated to be growing at a CAGR of 8.36%, to reach USD 2.06 billion by 2027.
Diabetic neuropathy is a nervous disorder associated with diabetes mellitus. Neuropathy is seen as a common complication for both type 1 and type 2 diabetes.
The European diabetic neuropathy market is being driven by the rising incidence and prevalence of diabetes and the rising comorbidities associated with diabetes, such as blindness and nerve damage.
Other significant factors expected to boost the growth of the global diabetic neuropathy market include an increasing geriatric population, sedentary lifestyles, urbanization linked to changes in eating habits, genetic composition, and rising incidence of chronic diseases such as obesity and cardiovascular disease. The thighs, hips, buttocks, and legs are affected by proximal diabetic neuropathy. Because of the persistent pain associated with diabetic neuropathy, daily activities might be tough. For more than 25 years, patients with neuropathy have had the highest prevalence of the condition. As a result, the treatment of diabetes has increased, with huge pharmaceutical companies investing considerably in new diabetic medications.
In the near future, factors such as the rising demand for better neuropathy medications are projected to create several market growth prospects. In addition, many local governments and non-governmental organizations (NGOs) around Europe are launching campaigns to promote awareness about diabetic neuropathy prevention. The National Institute of Neurological Disorders and Stroke, for example, funds neuropathy and related problems research.
However, The high costs associated with neuropathy therapy are projected to limit the global diabetic neuropathy market's expansion. The National Institute of Neurological Disorders and Stroke (NINDS) is investing money in neuropathy research. Governments and a number of non-governmental organizations (NGOs) in many countries are working to raise awareness about diabetic neuropathy prevention and management. However, high clinical trial failure rates and tight government rules for product authorization limit the Europe Diabetic Neuropathy Market.
In terms of pain alleviation, the medications used to treat neuropathic pain have had mixed results. A hurdle to the Diabetic Neuropathy Market is the incorrect diagnosis or therapy selection, as well as side effects and the rising cost of medications for the treatment of diabetic neuropathy. The European study linked neuropathy to diabetes and found that the majority of patients with clinically confirmed diabetes are at high risk of acquiring neuropathy.
This research report on the Europe diabetic neuropathy market has been segmented and sub-segmented into the following categories:
By Disorder:
By Treatment:
By Distribution Channel:
By Country:
The Europe Diabetic Neuropathy Market is predicted to grow at a rapid rate during the forecast period. Europe Pacific is predicted to develop at a 7.7% CAGR. The diabetic neuropathy market in Europe is being driven by rising diabetes prevalence and an increase in the geriatric population suffering from chronic disease. Furthermore, the rising number of diabetic patients in developed nations such as Germany, the UK, Italy, France, and Spain are predicted to propel the EUROPE Diabetic Neuropathy Market. Of all the individuals with diabetes worldwide, more than 60% live in Europe.
Germany dominated the Diabetic Neuropathy market over the forecast period. However, the market is anticipated to account for a substantial share in the coming years. The rising prevalence of diabetes and the growing geriatric population suffering from chronic disease are pushing the diabetic neuropathy market in the country. In addition, the availability of advanced healthcare infrastructure, increasing healthcare spending, and supportive government policies are fuelling the market growth.
On the other hand, the UK is likely to witness a major share in the diabetic neuropathy market owing to the growing number of health care awareness programs, hospitals equipped with X-ray machines to treat diabetic neuropathy, and numerous patients.
KEY MARKET PLAYERS:
Johnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Pfizer Inc., Astellas Pharma Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC and Depomed, Inc. are a few of the promising players in the Europe diabetic neuropathy market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region